Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing–Remitting and Primary Progressive Multiple Sclerosis
How can a disease be diagnosed, let alone be treated, when there are no identified common phenotype is manifested in several stages of progression? Compounding this reality, Multiple Sclerosis (MS) patients are often diagnosed at later stages of the disease.
Murgia et al. conducted a metabolomics study on serum and cerebrospinal fluid of patients suffering from MS. There are three types of MS (relapsing (RRMS), primary progressive (PPMS), and secondary progressive (SPMS)). Patients from the first two types were compared in this study.
Changes in metabolic profiles between the patient groups were found to be of high selectivity and specificity, which creates hope for a better suited MS future laboratory test. Additionally, metabolomics can also provide insights into the biology of the disease as the authors point out in the discussion of the study.
If you are interested in finding more about biomarkers research , please have a look at our products or contact us.
Federica Murgia, Lorena Lorefice, Simone Poddighe, Giuseppe Fenu, Maria Antonietta Secci, Maria Giovanna Marrosu, Eleonora Cocco, Luigi Atzori: Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing–Remitting and Primary Progressive Multiple Sclerosis. J. Clin. Med 2020 https://doi.org/10.3390/jcm9030863
